Medical Devices · Published Aug 2026
Sepsis Diagnostics Market
The global sepsis diagnostics market is projected to expand from USD 1,233.1 million in 2025 to USD 3,227.6 million by 2035, reflecting a compound annual growth rate (CAGR) of 10.1%. This trajectory underscores the escalating demand for rapid, accurate diagnostic solutions amid rising sepsis incidence and healthcare cost pressures. In Q1 2025, Abbott launched its Alinity m STI assay, which includes sepsis pathogen detection capabilities, signaling a strategic pivot toward integrated diagnostic platforms.
Medtronic, through its acquisition of Eko Health in January 2025, reinforced its presence in point-of-care diagnostics, further validating the convergence of digital health and sepsis detection. The market’s growth is also fueled by regulatory initiatives, such as the FDA’s 2025 guidance on sepsis biomarker development, which has accelerated innovation cycles among incumbents like Becton Dickinson (BD) and Stryker.
Market size
Growth trajectory through 2035
Sepsis Diagnostics Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Abbott received FDA 510(k) clearance for its Alinity m STI/Sepsis panel on March 15, 2025, enabling simultaneous detection of 15 pathogens and 3 resistance markers in a single run.
-
2025 Q2 2025
- BD launched the BACTEC FX400 automated blood culture system on April 22, 2025, featuring AI-driven contamination prediction and a 30% faster workflow compared to predecessor models.
-
2025 Q3 2025
- BioFire (bioMérieux) expanded its FilmArray BCID panel to include 5 new fungal targets on July 10, 2025, following a multicenter clinical validation study involving 1,200 sepsis cases.
-
2025 Q4 2025
- Roche Diagnostics received FDA approval for its cobas sepsis assay in neonatal cases on October 3, 2025, marking the first NGS-based sepsis test cleared for infants under 28 days.
Emerging opportunities added
- AI-Enabled Sepsis Prediction Models Startups like Current Health (acquired by Best Buy in 2025) are deploying machine learning algorithms to predict sepsis 6–12 hours before clinical onset. Their 2025 pilot with Mayo Clinic reduced false alarms by 35% compared to traditional early warning scores.
- Decentralized and Wearable Diagnostics The integration of sepsis biomarkers into wearable devices, such as Masimo’s Root platform with continuous lactate monitoring, opens a USD 500 million niche. The FDA’s 2025 draft guidance on wearable diagnostics is expected to accelerate this segment’s growth.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.23 Bn
- CAGR
- 10.10%
- Expansion
- 2.6×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- Hospitals (55%)
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Cost of Advanced Diagnostics
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Abbott received FDA 510(k) clearance for its Alinity m STI/Sepsis panel on March 15, 2025, enabling simultaneous detection of 15 pathogens and 3 resistance markers in a single run
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 95-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Sepsis Diagnostics Market today ($1.23 Bn base), and how fast will it grow at 10.1% CAGR through 2035?
- Which of Blood culture media (35%) holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Lab diagnostics (60%) applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising Sepsis Incidence and Mortality) and top restraints (led by High Cost of Advanced Diagnostics), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising Sepsis Incidence and Mortality The global sepsis burden has surged by 15% since 2020, with over 48 million cases reported annually, according to the Global Sepsis Alliance. This uptick is particularly acute in ICU settings, where delayed diagnosis correlates with a 20% increase in mortality rates. Automated blood culture systems, such as BD’s BACTEC FX, have reduced de…
- Technological Advancements in Rapid Diagnostics The FDA’s 2025 approval of T2 Biosystems’ T2Candida Panel for fungal sepsis detection marked a milestone in molecular diagnostics. Similarly, BioFire’s FilmArray Blood Culture Identification panel, launched in Q3 2025, now supports 30+ pathogens, enabling clinicians to tailor antimicrobial therapy within 6 hours of sample collec…
- Government and Regulatory Support The U.S. CDC’s 2025 Sepsis Core Elements framework mandates early warning systems in all Medicare-certified hospitals, creating a USD 200 million procurement pipeline for vendors like Medtronic and Stryker. The EU’s Horizon Europe program allocated EUR 120 million in 2025 to sepsis research, fostering public-private partnerships with firms li…
- Growing Demand for Point-of-Care Testing The point-of-care (POC) segment, valued at USD 310 million in 2025, is expanding at a 12.3% CAGR due to decentralized healthcare models. Abbott’s i-STAT Alinity system, cleared by the FDA in Q2 2025, exemplifies this trend, offering lab-quality results in under 15 minutes for procalcitonin and lactate assays.
Restraints
Holding it back
- High Cost of Advanced Diagnostics Automated sepsis platforms, such as BioMérieux’s VIDAS system, carry price tags exceeding USD 150,000, limiting adoption in low-resource settings. In Sub-Saharan Africa, where 60% of sepsis cases occur, the average per-capita healthcare expenditure is USD 45, rendering high-tech solutions inaccessible without external funding.
- Reimbursement Challenges and Pricing Pressures Medicare’s 2025 proposal to reduce reimbursement rates for sepsis-related tests by 8% has prompted pushback from diagnostics firms. Zimmer Biomet’s 2025 lobbying efforts, aimed at preserving reimbursement parity for molecular assays, highlight the industry’s vulnerability to policy shifts.
- False Positives and Diagnostic Uncertainty A 2025 meta-analysis published in *Critical Care* revealed that 18% of sepsis diagnoses based on procalcitonin levels were false positives, leading to unnecessary antibiotic use and contributing to antimicrobial resistance. This has slowed the adoption of biomarker-based tests in conservative markets like Japan.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Sepsis Incidence and Mortality | +4.5% | Global | 2025–2035 |
| Technological Advancements in Rapid Diagnostics | +2.8% | Global | 2025–2035 |
| Government and Regulatory Support | +2.2% | Global | 2025–2035 |
| Growing Demand for Point-of-Care Testing | +1.5% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of Advanced Diagnostics | −1.8% | Global | 2025–2029 |
| Reimbursement Challenges and Pricing Pressures | −1.2% | Global | 2025–2029 |
| False Positives and Diagnostic Uncertainty | −0.9% | Global | 2025–2029 |
The sepsis diagnostics market is segmented by product type, application, and end-user, with blood culture media and reagents dominating the product landscape at 35% and 28% market share, respectively, in 2025. Instruments and software, including AI-driven analytics, collectively account for 22%, while assays and microfluidics technologies round out the remaining 15%. By application, lab-based diagnostics lead with 60% of the market, but point-of-care testing is growing at 12.3% CAGR, driven by emergency departments and outpatient clinics. End-user analysis reveals hospitals as the largest segment at 55%, followed by pathology labs (25%), research laboratories (12%), and academic institutes (8%). The latter category is expanding fastest due to NIH-funded initiatives like the 2025 Sepsis Translational Research Program.
Revenue share by type · 2025 base year
% OF $1.23 BN SEPSIS DIAGNOSTICS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $1.23 Bn Sepsis Diagnostics Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Blood culture media (35%)
By application
-
Lab diagnostics (60%)
By end-user industry
-
Hospitals (55%)
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.23 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.6% in 2025. North America commands a 42% share of the global sepsis diagnostics market in 2025, with the U.S. alone accounting for 85% of regional revenue. The dominance stems from high healthcare spending (USD …
Per-region detail
-
North America
North America commands a 42% share of the global sepsis diagnostics market in 2025, with the U.S. alone accounting for 85% of regional revenue. The dominance stems from high healthcare spending (USD 12,555 per capita) and early adoption of AI-driven platforms like Medtronic’s 2025 acquisition of Eko Health. Canada’s 2025 federal budget allocated CAD 50 million to sepsis research, further solidifying the region’s leadership
-
Europe
Europe holds a 28% market share, with Germany and the UK as primary growth engines. The EU’s 2025 In Vitro Diagnostic Regulation (IVDR) has spurred demand for CE-marked assays, such as BioMérieux’s VIDAS system, which saw a 15% uptick in sales post-compliance. France’s 2025 sepsis action plan, targeting a 25% reduction in mortality by 2030, has also driven procurement of rapid diagnostic tools
-
Asia-Pacific
The Asia-Pacific region is the fastest-growing at 13.2% CAGR, with China and India leading the charge. China’s 2025 “Healthy China 2030” initiative earmarked USD 1.2 billion for infectious disease diagnostics, benefiting local players like BGI Group. Japan’s aging population, coupled with a 20% rise in sepsis cases among the elderly, has prompted partnerships between Stryker and Japanese diagnostics firms to localize POC solutions
-
Latin America
Latin America’s market, valued at USD 85 million in 2025, is constrained by economic instability but shows promise in Brazil and Mexico. The 2025 launch of Abbott’s Alinity m in Brazil’s public health system, following a USD 15 million tender, exemplifies incremental growth through public-private collaborations
-
Middle East & Africa
The Middle East & Africa segment, representing 5% of global revenue, is characterized by high unmet needs and donor-funded initiatives. South Africa’s 2025 National Health Insurance pilot includes sepsis diagnostics as a priority, while the WHO’s 2025 Africa Sepsis Program has catalyzed partnerships with BD to deploy low-cost blood culture systems in 100+ hospitals
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The sepsis diagnostics market exhibits moderate fragmentation, with the top five players—BD, Abbott, BioMérieux, BioFire (bioMérieux), and Roche—controlling 58% of the market in 2025. BD’s 2025 acquisition of CUBRC’s sepsis diagnostics division strengthened its portfolio, while Abbott’s Q1 2025 launch of the Alinity m STI/Sepsis panel underscored its pivot toward multiplexed testing. Mergers and acquisitions have accelerated, with Stryker’s 2025 purchase of a minority stake in Israel’s DayTwo, a microbiome-based sepsis prediction firm, signaling convergence with precision medicine.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of the Sepsis Diagnostics market
The Sepsis Diagnostics market size had crossed USD 32.50 million in 2020 and will observe a CAGR of more than 8.85% up to 2029 driven by the rise in sepsis diseases and diagnostic surgeries in healthcare industry.
-
• What is the size of the North America Sepsis Diagnostics industry?
North America accounted for a 42% share of the sepsis diagnostics market in 2020 and is expected to maintain its dominance during the forecast period.
-
• What are the challenges, drivers and opportunities for the Sepsis Diagnostics market?
Rising number of sepsis occurrences, and growing government programmes to raise sepsis awareness are all likely to drive demand for sepsis diagnostic devices and thus market growth. Development of quick diagnosis/point-of-care approaches for early sepsis diagnoses is expected to create lucrative opportunities to major industry participants. But the high cost of automated diagnostics instruments limits the market expansion. -
• Which are the top companies to hold the market share in Sepsis Diagnostics market?
bioMérieux, Becton, Dickinson and Company, Danaher Corporation, T2 Biosystems, Luminex, Roche Diagnostics, Thermo Fisher Scientific, Bruker Corporation, Abbott Laboratories, Immunexpress, Axis-Shield Diagnostics, Quidel Corporation, and others., are among the leading players in the global sepsis diagnostics market. -
• Which is the largest regional market for Sepsis Diagnostics Market?
Presence of a highly developed healthcare system, high adoption of innovative sepsis diagnostic technologies among medical professionals, a rising number of surgical procedures, in the North American region, it accounted for a large share of sepsis diagnostics market in 2020 and is expected to maintain its dominance during the forecast period. -
• Which region is expected to have the fastest growth rate within the forecast period?
Due to its large patient population, increasing sepsis diagnostics usage in healthcare industry, as well as the rise in geriatric population, Asia-Pacific is expected to have the highest CAGR in coming years.
The Sepsis Diagnostics Market is projected to reach $3.22 Bn by 2035, up from $1.23 Bn in 2025 — a 10.10% CAGR equating to roughly 2.6× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.